Answer
Deucravacitinib does not meaningfully affect plasma exposure to oral contraceptives containing norethindrone acetate and ethinyl estradiol, and no dose adjustments are needed.
Sources for this answer
- SOTYKTU 6 mg film coated tabletsBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked